• search hit 16 of 1102
Back to Result List

Matching anticancer compounds and tumor cell lines by neural networks with ranking loss

  • Computational drug sensitivity models have the potential to improve therapeutic outcomes by identifying targeted drug components that are likely to achieve the highest efficacy for a cancer cell line at hand at a therapeutic dose. State of the art drug sensitivity models use regression techniques to predict the inhibitory concentration of a drug for a tumor cell line. This regression objective is not directly aligned with either of these principal goals of drug sensitivity models: We argue that drug sensitivity modeling should be seen as a ranking problem with an optimization criterion that quantifies a drug's inhibitory capacity for the cancer cell line at hand relative to its toxicity for healthy cells. We derive an extension to the well-established drug sensitivity regression model PaccMann that employs a ranking loss and focuses on the ratio of inhibitory concentration and therapeutic dosage range. We find that the ranking extension significantly enhances the model's capability to identify the most effective anticancer drugs forComputational drug sensitivity models have the potential to improve therapeutic outcomes by identifying targeted drug components that are likely to achieve the highest efficacy for a cancer cell line at hand at a therapeutic dose. State of the art drug sensitivity models use regression techniques to predict the inhibitory concentration of a drug for a tumor cell line. This regression objective is not directly aligned with either of these principal goals of drug sensitivity models: We argue that drug sensitivity modeling should be seen as a ranking problem with an optimization criterion that quantifies a drug's inhibitory capacity for the cancer cell line at hand relative to its toxicity for healthy cells. We derive an extension to the well-established drug sensitivity regression model PaccMann that employs a ranking loss and focuses on the ratio of inhibitory concentration and therapeutic dosage range. We find that the ranking extension significantly enhances the model's capability to identify the most effective anticancer drugs for unseen tumor cell profiles based in on in-vitro data.show moreshow less

Export metadata

Additional Services

Search Google Scholar Statistics
Metadaten
Author details:Paul PrasseORCiDGND, Pascal IversenORCiD, Matthias LienhardORCiDGND, Kristina Thedinga, Christopher BauerORCiDGND, Ralf HerwigORCiD, Tobias SchefferORCiD
DOI:https://doi.org/10.1093/nargab/lqab128
ISSN:2631-9268
Pubmed ID:https://pubmed.ncbi.nlm.nih.gov/35047818
Title of parent work (English):NAR: genomics and bioinformatics
Publisher:Oxford Univ. Press
Place of publishing:Oxford
Publication type:Article
Language:English
Date of first publication:2022/01/14
Publication year:2022
Release date:2024/01/05
Volume:4
Issue:1
Article number:lqab128
Number of pages:10
Funding institution:German Federal Ministry of Research and Education [01IS18044]
Organizational units:Mathematisch-Naturwissenschaftliche Fakultät / Institut für Informatik und Computational Science
DDC classification:0 Informatik, Informationswissenschaft, allgemeine Werke / 00 Informatik, Wissen, Systeme / 000 Informatik, Informationswissenschaft, allgemeine Werke
5 Naturwissenschaften und Mathematik / 57 Biowissenschaften; Biologie / 570 Biowissenschaften; Biologie
Peer review:Referiert
Publishing method:Open Access / Gold Open-Access
DOAJ gelistet
License (German):License LogoCC-BY - Namensnennung 4.0 International
Accept ✔
This website uses technically necessary session cookies. By continuing to use the website, you agree to this. You can find our privacy policy here.